Answers are grounded in this paper and cite their sources.
This review summarizes observations of clinical use of high dose intravenous immunoglobulin G (IVIg) in regards to administration, kinetics, known or postulated mechanisms of action, and adverse reactions. Indications and value of IVIg for the treatment of various neuropathies with presumed autoimmune aetiology are examined. New knowledge that advances the understanding of the pathogenesis of the neuropathies and of the mechanisms of action of IVIg is discussed.
No takes yet. Share an insight, caveat, or question.
Angelika F. Hahn (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: